PGE2

Biomarker

Also known as: PGE2

Related News

Advances in CAR T-Cell Control: Dual Receptor Knockout and Drug-Regulated Switches

Feb 28, 2026

Researchers develop multiple strategies to enhance CAR T-cell therapy, including dual PGE2 receptor knockout for solid tumors and small-molecule switches using venetoclax and caffeine to control cellular activity and improve safety.

CAR T-Cell Therapy Advances Target Solid Tumors and Selective Cancer Killing

Feb 14, 2026

Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.